Fresenius Kabi, Samsung Bioepis lock horns again over Humira biosimilar
German biotech Fresenius Kabi has struck back at Samsung Bioepis’s latest attack on the validity of its patents for a liquid formulation of top selling immunosuppressant drug Humira, accusing the Korean company of causing its sales to flag by infringing the patent.
For information on rights and reprints, contact subscriptions@lawyerly.com.au